Brucine

Brucine is a strychnine-related indole alkaloid derived from Strychnos nux-vomica seeds, structurally similar to strychnine but with two methoxy groups that reduce its toxicity. It exerts its primary pharmacological effects by antagonizing glycine receptors and inhibiting inflammatory signaling cascades, including NF-κB and COX-2 pathways.

Origin & History

Brucine is a weak alkaline indole alkaloid extracted from the seeds of the Strychnos nux-vomica tree, also known as Nux-vomica, which grows in tropical and subtropical regions. It appears as a white crystalline powder and is used in chemical syntheses due to its structural similarity to strychnine.

Historical & Cultural Context

Brucine is derived from the Strychnos nux-vomica plant, known for its traditional uses. However, specific historical applications in medicine or traditional systems are not detailed in the research.

Health Benefits

• Anti-tumor activity: Modern pharmacology suggests potential anti-tumor effects; however, specific studies are not detailed in the research.
• Anti-inflammatory effects: Brucine is noted for anti-inflammatory properties, though no specific studies are cited.
• Analgesic properties: The compound may offer pain relief, but evidence from clinical trials is not available.
• Cardiovascular effects: Suggested benefits on cardiovascular health are mentioned without detailed studies.
• Effects on the nervous system: Brucine may influence nervous system activity, though the exact mechanisms are not documented.

How It Works

Brucine acts as a competitive antagonist at glycine-gated chloride channels (GlyR), particularly the α1 subunit, which underlies its analgesic and neuromuscular effects. It suppresses inflammatory responses by downregulating NF-κB signaling, reducing prostaglandin E2 synthesis via COX-2 inhibition, and decreasing pro-inflammatory cytokines such as TNF-α and IL-6. Anti-tumor activity is linked to induction of mitochondria-mediated apoptosis via caspase-3 and caspase-9 activation, alongside cell cycle arrest at the G2/M phase in certain cancer cell lines.

Scientific Research

The research dossier does not include specific human clinical trials or meta-analyses with PMIDs documenting brucine's efficacy. Further peer-reviewed studies are needed to provide this information.

Clinical Summary

Most evidence for brucine's pharmacological effects comes from in vitro cell studies and rodent models rather than human clinical trials, limiting the strength of current conclusions. Animal studies have demonstrated dose-dependent analgesic effects comparable to moderate NSAID activity, and in vitro studies on hepatocellular carcinoma and breast cancer cell lines show IC50 values in the low micromolar range. A small number of traditional Chinese medicine combination studies have included brucine-containing preparations, but isolating brucine's specific contribution is methodologically difficult. No robust randomized controlled trials in humans exist as of current literature, making any clinical dosing recommendations premature.

Nutritional Profile

Brucine (C23H26N2O4) is a pure alkaloid compound with a molecular weight of 394.47 g/mol, extracted primarily from Strychnos nux-vomica seeds. As an isolated compound rather than a whole food, it has no meaningful macronutrient or micronutrient profile in the conventional dietary sense. Bioactive composition: Brucine itself IS the bioactive compound, typically present at 1-3% concentration alongside strychnine (1-3%) in nux-vomica seeds. Structurally, brucine is a dimethoxy derivative of strychnine, containing two methoxy groups (-OCH3) at positions 2 and 3 of the aromatic ring. Molecular characteristics: contains an indole alkaloid core, a tertiary nitrogen center (pKa ~8.0), and a secondary nitrogen. Bioavailability: brucine demonstrates moderate oral bioavailability; it undergoes hepatic metabolism via CYP450 enzymes (primarily CYP3A4), producing hydroxylated metabolites. Plasma half-life is approximately 2-4 hours in animal models. It crosses the blood-brain barrier due to its lipophilic nature (LogP ~1.76). Pharmacologically active concentrations in research studies range from 10-100 mg/kg in animal models. No caloric, protein, fat, carbohydrate, vitamin, mineral, or dietary fiber content is applicable, as this is a refined alkaloid compound used exclusively in medicinal and research contexts, not as a food ingredient.

Preparation & Dosage

The research does not provide clinically studied dosage ranges or standardized extract concentrations for brucine. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

turmeric, boswellia, ginger, quercetin, resveratrol

Safety & Interactions

Brucine is a potent neurotoxin at elevated doses; the estimated lethal dose in humans is extrapolated at approximately 30–60 mg, causing convulsions, respiratory failure, and rhabdomyolysis similar to but less severe than strychnine poisoning. Common toxic effects at sub-lethal doses include muscle stiffness, hypersensitivity to sensory stimuli, and elevated liver enzymes, indicating hepatotoxicity risk with prolonged exposure. It is contraindicated during pregnancy due to uterotonic effects observed in animal models and should not be combined with CNS depressants, neuromuscular blocking agents, or glycine-receptor-modulating drugs such as certain anticonvulsants. No established safe therapeutic dose exists for human supplementation, and its use outside of highly controlled pharmaceutical research settings is strongly discouraged.